Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening.

Structure-based computational screening of the National Cancer Institute database of anticancer compounds identified novel non-nucleobase-derived inhibitors of human thymidine phosphorylase as candidates for lead optimization. The hierarchical in silico screening strategy predicted potentially strong low molecular weight ligands exhibiting a range of molecular scaffolds. Of the thirteen ligands assayed for activity, all displayed inhibitory activity against Escherichia coli thymidine phosphorylase. One compound, hydrazine carboxamide 2-[(1-methyl-2,5-dioxo-4-pentyl-4-imidazolidinyl)methylene], was found to inhibit E. coli thymidine phosphorylase with an IC(50) value of 20 microM and an IC(50) value of 77 microM against human thymidine phosphorylase. As this hydantoin derivative lacks the undesirable ionic sites of existing tight-binding nucleobase-derived inhibitors, such as 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]uracil hydrochloride, it provides an opportunity for the design of potent thymidine phosphorylase inhibitors with improved pharmacokinetic properties.

[1]  I. Stratford,et al.  Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. , 2003, Journal of medicinal chemistry.

[2]  W. Cook,et al.  Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 A resolution. , 1991, The Journal of biological chemistry.

[3]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[4]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[5]  D. Marks,et al.  A similarity model for the human angiogenic factor, thymidine phosphorylase/platelet derived-endothelial cell growth factor. , 1999, Anti-cancer drug design.

[6]  T. Furukawa,et al.  Angiogenic activity of enzymes , 1994, Nature.

[7]  S. Fox,et al.  Thymidine phosphorylase is angiogenic and promotes tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Kollman,et al.  An all atom force field for simulations of proteins and nucleic acids , 1986, Journal of computational chemistry.

[9]  Albert J. Leo,et al.  Calculating log P(oct) with no missing fragments; The problem of estimating new interaction parameters , 2000 .

[10]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[11]  M. Fukushima,et al.  The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. , 1999, Cancer research.

[12]  J. Gasteiger,et al.  Automatic generation of 3D-atomic coordinates for organic molecules , 1990 .

[13]  S. Chu,et al.  Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases. , 1983, Biochemical pharmacology.

[14]  R. Esnouf,et al.  Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase , 2000, FEBS letters.

[15]  Y. Wataya,et al.  Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2'-deoxyuridine as substrate. , 1981, Analytical Biochemistry.

[16]  S. Akiyama,et al.  Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. , 1995, Cancer research.

[17]  K. Hotchkiss,et al.  Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. , 2001, Biochemical pharmacology.

[18]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[19]  A. Yoshimura,et al.  Angiogenic factor , 1992, Nature.

[20]  A. Jasanoff,et al.  Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. , 1998, Journal of molecular biology.

[21]  W. Guida,et al.  Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model. , 2003, Bioorganic & medicinal chemistry letters.

[22]  N. Suzuki,et al.  Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. , 2000, Biochemical pharmacology.